Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate

Seminars in Radiation Oncology

Volumn 13, Issue 2, 2003, Pages 141-151

  Lawton, Colleen A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; MEGESTROL ACETATE; NILUTAMIDE;

ADVANCED CANCER; ANEMIA; BLADDER NECK STENOSIS; CANCER RADIOTHERAPY; CASTRATION; CLINICAL TRIAL; DIARRHEA; DOG; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; REVIEW;

EID: 0038304594     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)70007-1     Document Type: Review

References (36)

1. White JW: The present position of the surgery of the hypertrophied prostate. Ann Surg 18:152-188, 1893
2. Huggins C, Clark PJ: Quantitative studies of prostatic secretion, II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med 72:747, 1940
3. Huggins C, Hodges C: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Studies on prostate cancer. Cancer Res 1:293-297, 1941
4. Huggins C, Stevens RE, Hodges C: The effect of castration on advanced carcinoma of the prostate gland. Studies on prostate cancer. Arch Surg 43:209-223, 1941
5. Walsh PC. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2:125-140, 1975
6. Hanks GE, Myers CE, Scardino PT: Cancer of the prostate, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology. Philadelphia PA, Lippincott JB, 1993, pp 1073-1113
7. Green N, Melbye R, Lipsett J, et al: Measures to improve therapeutic response and prevent complication. Urology 3:287-290, 1975
8. van der Werf-Messing B: Prostatic cancer treated at the Rotterdam Radiotherapy Institute. Strahlentherapie 154: 537-541, 1978
9. Camuzzi F, Block N, Stover B, et al: Investigation of different combinations of estrogen therapy and radiation therapy on prostatic adenocarcinoma. Urology 15:443-447, 1980
10. Green N, Bodner H, Broth E, et al: Response of lymph node metastasis to sequential estrogen and radiation therapy in prostate carcinoma. Urology 18:137-142, 1981
11. Green N, Chang C, Goldberg H, et al: Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 10:971-976, 1984
12. 1 carcinoma of the prostate. J Urol 139:1242-1244, 1988
13. Pilepich MV, Krall JM, John J, et al: Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: Preliminary results of RTOG 83-07. Int J Radiat Oncol Bio Phys 16:813-817, 1989
14. Porter AT, Venner PM: The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer - The Canadian Perspective. EORTC Genitourinary Group Monogram 8 Treatment of Prostatic Cancer Facts and Controversies. Wiley-Liss Inc, 1990, pp 231-237
15. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
16. Pilepich MV, Winter K, John MJ, et al: Phase III RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252, 2001
17. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
18. Lawton CA, Winter K, Murray K, et al: Updated results of the phase III RTOG trial 85-31. Evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937-946, 2001
19. Pilepich MF, Krall, JM, Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
20. st Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys 45:147, 1999
21. Horwitz EM, Winter K, Hanks GE, et al: Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49:947-956, 2001
22. Hanks GE, Lu D, Machtay M, et al: RTOG Protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 48:112, 2000
23. Laverdiere J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247-252, 1997
24. rd annual ASTRO meeting. Int J Radiat Oncol Biol Phys 51:3, 2001
25. Roach III M, Lu J, Pilepich M, et al: Predicting long-term survival and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47:617-627, 2000
26. Makarov D, Sanderson H, Partin A, et al: Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 167:2440-2442, 2002
27. Stege R: Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 10:38-42, 2000
28. Townsend MF, Sanders WH, Northway RO, et al: Associated with luteining hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545-550, 1997
29. Berruti A, Dogliotti L, Terrone C, et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given given androgen deprivation therapy. J Urol 167: 2361-2367, 2002
30. McLead DG, Vogelzang NJ: Initial management of metastatic prostate cancer, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Philadelphia PA, Lippincott, 2000, pp 824-854
31. Cox J, Lu J, Pilepich M, et al. Does hormone therapy influence the risk of late effects in normal tissues irradiated for carcinoma of the prostate? Data from prospective trials of the RTOG. Presented at Am Radium Society (ARS), Monte Carlo, CA, April 4-8, 1998
32. Bolla M, Collette L, Blank L, et al: Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103-108, 2002
33. Neymark N, Adriaenssen I, Gorelia T, et al: Estimating survival gain for economic evaluations with survival time as principal endpoints: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 11:233-248, 2002
34. Roach MRE: The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1923-1924, 1993
35. Roach M, Marquez C, You H, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33-37, 1993
36. Ross RW, Small EJ: Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952-1956, 2002